



**AMENDMENTS TO THE CLAIMS**

Cancel claims 32-38 without prejudice, and amend the claims as shown below.

1-22 (Cancelled)

23. (**Currently amended**) A glycopeptide antibiotic or derivative thereof according to formula I, II or III:





Formula III

wherein:

- each  $b^1$  and  $b^2$  independently represents nihil or an additional bond, while  $b^1$  and  $b^2$  cannot be an additional bond at the same time,  $R^0$  represents nihil when  $b^2$  represents an additional bond and hydrogen when  $b^2$  represents nihil,  $R^6$  represents nihil when  $b^1$  represents an additional bond and hydrogen when  $b^1$  represents nihil,  $R^6$  represents  $R^{6a}$  and  $R^0$  represents hydrogen when  $b^1$  and  $b^2$  each represents nihil;
- $b^3$  represents nihil or an additional bond,  $R^a \cdots R^{5a}$  represents a group of the formula  $CHN(R^{11})CO$ ,  $CHN(R^{11})(CH_2)_z N(R^{11a})CO$  or  $CHN(R^{11})CO(CH_2)_z N(R^{11a})CO$  when  $b^3$  represents an additional bond, and  $R^a$  is R and  $R^{5a}$  is  $R^5$  when  $b^3$  represents nihil, wherein z is 0, 1, 2, 3 or 4;
- $b^4$  represents nihil or an additional bond,  $R^b \cdots R^{5b}$  represents a group of the formula  $CHN(R^{11})CO$ ,  $CHN(R^{11})(CH_2)_z N(R^{11a})CO$  or  $CHN(R^{11})CO(CH_2)_z N(R^{11a})CO$  when  $b^4$  represents an additional bond, and  $R^b$  is R and  $R^{5b}$  is  $R^5$  when  $b^4$  represents nihil, wherein p is 0, 1, 2, 3 or 4;

- each  $b^5$ ,  $b^6$  and  $b^7$  independently represents nihil or an additional bond; Y represents oxygen,  $R^{0a}$  represents hydrogen and  $R^d$  represents R or a group of the formula  $(CH_2)_qCON(R^{11})CH(CH_2OH)(CH_2)_qN(R^{12})CH(CH_2OH)$  when  $b^5$  and  $b^7$  represent nihil and  $b^6$  represents an additional bond;  $R^{0a}$  represents nihil,  $R^d---Y$  represents a group of the formula  $CHN=C(NR^{11})O$  or  $CHNHCON(R^{11})$  when  $b^6$  represents nihil and  $b^5$  represents an additional bond. Y and  $R^{0a}$  each represents a hydrogen and  $R^d$  represents group of the formula  $(CH_2)_qCON(R^{11})CH(CH_2OH)(CH_2)_qN(R^{12})CH(CH_2OH)$  when  $b^5$ ,  $b^6$  and  $b^7$  each represents nihil, wherein q is 0, 1, 2, or 3 and n is 0, 1, 2 or 3;
- each  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$ ,  $X^7$  and  $X^9$  are independently selected from the group consisting of hydrogen, halogen and  $X^6$ ;
- $X^6$  is selected from the group ~~comprising~~ consisting of hydrogen, halogen,  $SO_2H$ , OH, NO,  $NO_2$ ,  $NHNH_2$ ,  $NHN=CHR^{11}$ ,  $N=NR^{11}$ ,  $CHR^{11}R^{13}$ ,  $CH_2N(R^3)R^{11}$ ,  $R^5$ ,  $R^{11}$  and  $R^{13}$ , wherein  $R^3$  is  $CH_2$  attached to the phenolic hydroxyl group of the 7<sup>th</sup> amino acid;
- $X^8$  is selected from the group consisting of hydrogen and alkyl;
- $R^c$  represents R and  $R^{5c}$  represents  $R^5$ ;
- R is selected from the group consisting of  $CHR^{13}$  and  $R^{14}$ ;
- $R^1$  is selected from the group consisting of hydrogen,  $R^{11}$ ,  $(CH_2)_tCOOH$ ,  $(CH_2)_tCONR^{11}R^{12}$ ,  $(CH_2)_tCOR^{13}$ ,  $(CH_2)_tCOOR^{11}$ ,  $COR^{15}$ ,  $(CH_2)_tOH$ ,  $(CH_2)_tCN$ ,  $(CH_2)_tR^{13}$ ,  $(CH_2)_tSCH_3$ ,  $(CH_2)_tSOCH_3$ ,  $(CH_2)_tS(O)_2CH_3$ ,  $(CH_2)_tphenyl(m-OH, p-Cl)$ , and  $(CH_2)_tphenyl(o-X^7, m-OR^{10}, p-X^8)-[O-phenyl(o-OR^9, m-X^9, m-R^{16})]-m$ , where t is 0, 1, 2, 3 or 4;
- each  $R^2$  and  $R^4$  are independently selected from the group consisting of hydrogen,  $R^{12}$  and  $R^{17}$ ;
- $R^3$  is selected from the group consisting of hydrogen,  $R^{12}$ ,  $R^{17}$  and Sug;

- $R^5$  is selected from the group consisting of  $\text{COOH}$ ,  $\text{COOR}^{11}$ ,  $\text{COR}^{13}$ ,  $\text{COR}^{15}$ ,  $\text{CH}_2\text{OH}$ ,  $\text{CH}_2\text{halogen}$ ,  $\text{CH}_2\text{R}^{13}$ ,  $\text{CHO}$ ,  $\text{CH}=\text{NOR}^{11}$ ,  $\text{CH}=\text{NNR}^{11}\text{R}^{12}$  and  $\text{C}=\text{NNHCONR}^{11}\text{R}^{12}$ ;
- $R^{6a}$  is selected from the group consisting of  $\text{OR}^{12}$ ,  $\text{OR}^{17}$ ,  $\text{OH}$ ,  $\text{O-alkyl-Sug}$ ,  $\text{O-alkenyl-Sug}$ ,  $\text{O-alkynyl-Sug}$  and  $\text{O-Sug}$ , wherein each alkyl, alkenyl and alkynyl can be unsubstituted or substituted with 1 or more  $\text{R}^{19}$  or Sug;
- $R^7$  is selected from the group consisting of hydrogen,  $\text{R}^{12}$ ,  $\text{R}^{17}$ , Sug,  $\text{and O-alkyl-Sug}$ ,  $\text{alkenyl-Sug}$ , and  $\text{alkynyl-Sug}$ , wherein each alkyl, alkenyl and alkynyl can be unsubstituted or substituted with 1 or more  $\text{R}^{19}$  or Sug;
- $R^8$  is selected from the group consisting of hydrogen,  $\text{R}^{12}$ ,  $\text{R}^{17}$ ,  $\text{OH}$ ,  $\text{O-alkyl-Sug}$ ,  $\text{O-alkenyl-Sug}$ ,  $\text{O-alkynyl-Sug}$  and  $\text{O-Sug}$ , wherein each alkyl, alkenyl and alkynyl can be unsubstituted or substituted with 1 or more  $\text{R}^{19}$  or Sug;
- $R^9$  is selected from the group consisting of hydrogen,  $\text{R}^{12}$ ,  $\text{R}^{17}$  ~~or~~ and Sug;
- $R^{10}$  is selected from the group consisting of hydrogen,  $\text{R}^{12}$ ,  $\text{R}^{17}$  ~~or~~ and Sug, wherein Sug is any cyclic or acyclic carbohydrate;
- each  $\text{R}^{11}$ ,  $\text{R}^{11a}$  and  $\text{R}^{11b}$  are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, cyloalkyl, cycloalkenyl, cycloalkynyl, a heterocyclic ring, alkylphosphonate (e.g. ~~alkylene~~ $\text{PO}_2\text{OH}$ ) and alkylphosphonamide unsubstituted or substituted at the amide with alkyl, alkenyl or alkynyl (e.g. ~~alkylene~~ $\text{PO}_2\text{NH}_2$ ), wherein each alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, cyloalkyl, cycloalkenyl, cycloalkynyl and heterocyclic ring can be substituted with 1 or more  $\text{R}^{19}$  or Sug;
- each  $\text{R}^{12}$  and  $\text{R}^{12a}$  are independently selected from the group consisting of hydrogen, acyl, amino-protecting group, carbamoyl, thiocarbamoyl,  $\text{SO}_2\text{R}^{11}$ ,  $\text{S(O)R}^{11}$ ,  $\text{COR}^{13}\text{-R}^{18}$ ,  $\text{COCHR}^{18}\text{N(NO)R}^{11}$ ,  $\text{COCHR}^{18}\text{NR}^{11}\text{R}^{12}$  and  $\text{COCHR}^{18}\text{N}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$ , alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, cyloalkyl, cycloalkenyl, cycloalkynyl and a heterocyclic ring, wherein each alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl,

cyloalkyl, cycloalkenyl, cycloalkynyl and a heterocyclic ring can be substituted with 1 or more  $R^{19}$  or Sug;

-  $R^{13}$  is selected from the group consisting of hydrogen,  $NHR^{12a}$ ,  $NR^{11}R^{12}$ ,  $NR^{11}Sug$ ,  $N^+R^{11}R^{11a}R^{11b}$ ,  $R^{15}$ ,  $NR^{11}C(R^{11a}R^{11b})COR^{15}$  and a group of the formula  $N-A-N^+-A$ , wherein A is  $-CH_2-B-CH_2-$  and B is  $-(CH_2)_m-D-(CH_2)_r-$ , wherein m and r are from 1 to 4 and D is selected from the group consisting of O, S,  $NR^{12}$ , and  $N^+R^{11}R^{11a}$ ;

-  $R^{14}$  is selected from the group consisting of  $CH_2$ ,  $C=O$ ,  $CHOH$ ,  $C=NOR^{11}$ ,  $CHNHOR^{11}$ ,  $C=NNR^{11}R^{12}$ ,  $C=NNHCONR^{11}R^{12}$  and  $CHNHNr^{11}R^{12}$ ;

-  $R^{15}$  is selected from the group consisting of  $N(R^{11})NR^{11a}R^{12}$ ,  $N(R^{11})OR^{11a}$ , and  $NR^{11}C(R^{11a}R^{11b})COR^{13}$ ;

-  $R^{16}$  is selected from a the group consisting of the formula  $R-R^5$  or and  $CH(NH_2)CH_2OH$ ;

-  $R^{17}$  is selected from the group consisting of  $SO_3H$ ,  $SiR^{11}R^{11a}R^{11b}$ ,  $SiOR^{11}OR^{11a}OR^{11b}$ ,  $PR^{11}R^{11a}$ ,  $P(O)R^{11}R^{11a}$ , and  $P^+R^{11}R^{11a}R^{11b}$ ;

-  $R^{18}$  is selected from the group consisting of hydrogen,  $R^1$ , alkyl, aryl, phenyl-rhamnose-*p*, phenyl-(rhamnosegalactose)-*p*, phenyl-(galactose-galactose)-*p*, and phenyl-O-methylrhamnose-*p*, wherein each alkyl and aryl can be substituted with 1 or more  $R^{19}$  or Sug;

-  $R^{19}$  is selected from the group consisting of hydrogen, halogen, SH,  $SR^{20}$ , OH,  $OR^{20}$ , COOH,  $COR^{20}$ ,  $COOR^{20}$ ,  $NO_2$ ,  $NH_2$ ,  $N(R^{20})_2$ ,  $NHC(NH_2)=NH$ ,  $CH(NH_2)=NH$ ,  $NHOH$ ,  $NHNH_2$ ,  $N_3$ , NO, CN,  $N=NR^{20}$ ,  $N=NR^{12}$ ,  $SOR^{20}$ ,  $SO_2R^{20}$ ,  $PO_2OR^{20}$ ,  $PO_2N(R^{20})_2$ ,  $B(OH)_2$ ,  $B(OR^{20})_2$ , CO, CHO, O-Sug,  $NR^{20}$ -Sug,  $R^{20}$ ,  $R^{12}$ ,  $R^{17}$  and  $R^{18}$ , and each  $R^{19}$  can be substituted with 1 or more  $R^{20}$ ;

-  $R^{20}$  is selected from the group consisting of hydrogen, halogen, SH, OH, COOH,  $NO_2$ ,  $NH_2$ ,  $NHC(NH_2)=NH$ ,  $CH(NH_2)=NH$ ,  $NHOH$ ,  $NHNH_2$ ,  $N_3$ , NO, CN, alkyl, alkenyl,

alkynyl, aryl, arylalkyl, heteroaryl, cyloalkyl, cycloalkenyl, cycloalkynyl and a heterocyclic ring.

24. **(Currently amended)** The glycopeptide antibiotic or derivative thereof according to claim 23, wherein:

- each  $b^1$  and  $b^2$  represent nihil,  $R^6$  represents  $R^{6a}$  and  $R^0$  represents hydrogen;
- $b^3$  represents an additional bond and  $R^a \text{---} R^{5a}$  represents  $\text{CHNHCO}$ ;
- $b^4$  represents nihil or an additional bond,  $R^b \text{---} R^{5b}$  represents a group of the formula  $\text{CHN}(R^{11})\text{CO}$ ,  $\text{CHN}(R^{11})(\text{CH}_2)_z\text{N}(R^{11a})\text{CO}$  or  $\text{CHN}(R^{11})\text{CO}(\text{CH}_2)_p\text{N}(R^{11a})\text{CO}$  when  $b^4$  represents an additional bond, and  $R^b$  is R and  $R^{5b}$  is  $R^5$  when  $b^4$  represents nihil, wherein p is 0, 1, 2, 3 or 4;
- each  $b^5$ ,  $b^6$  and  $b^7$  independently represents nihil or an additional bond; Y represents oxygen,  $R^{0a}$  represents hydrogen and  $R^d$  represents R or a group of the formula  $(\text{CH}_2)_q\text{CON}(R^{11})\text{CH}(\text{CH}_2\text{OH})(\text{CH}_2)_q\text{N}(R^{12})\text{CH}(\text{CH}_2\text{OH})$  when  $b^5$  and  $b^7$  represent nihil and  $b^6$  represents an additional bond,  $R^{0a}$  represents nihil,  $R^d \text{---} Y$  represents a group of the formula  $\text{CHN}=\text{C}(\text{NR}^{11})\text{O}$  or  $\text{CHNHCON}(R^{11})$  when  $b^6$  represents nihil and  $b^5$  represents an additional bond, Y and  $R^{0a}$  each represents a hydrogen and  $R^d$  represents group of the formula  $(\text{CH}_2)_q\text{CON}(R^{11})\text{CH}(\text{CH}_2\text{OH})(\text{CH}_2)_q\text{N}(R^{12})\text{CH}(\text{CH}_2\text{OH})$  when  $b^5$ ,  $b^6$  and  $b^7$  each represents nihil, wherein q is 0, 1, 2, or 3 and n is 0, 1, 2 or 3;
- each  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$ ,  $X^7$  and  $X^9$  are independently selected from the group consisting of hydrogen and halogen;
- $X^6$  is  $\text{CH}_2\text{R}^{13}$ ;
- $X^8$  is selected from the group consisting of hydrogen and methyl;
- $R^c$  represents R and  $R^{5c}$  represents  $R^5$ ;

- R is CHR<sup>13</sup>;
- R<sup>1</sup> is selected from the group consisting of hydrogen, R<sup>11</sup>, (CH<sub>2</sub>)<sub>t</sub>COOH, (CH<sub>2</sub>)<sub>t</sub>CONR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>t</sub>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>t</sub>COOR<sup>11</sup>, COR<sup>15</sup>, (CH<sub>2</sub>)<sub>t</sub>OH, (CH<sub>2</sub>)<sub>t</sub>CN, (CH<sub>2</sub>)<sub>t</sub>R<sup>13</sup>, (CH<sub>2</sub>)<sub>t</sub>SCH<sub>3</sub>, (CH<sub>2</sub>)<sub>t</sub>SOCH<sub>3</sub>, (CH<sub>2</sub>)<sub>t</sub>S(O)<sub>2</sub>CH<sub>3</sub>, (CH<sub>2</sub>)<sub>t</sub>phenyl(*m*-OH, *p*-Cl), and (CH<sub>2</sub>)<sub>t</sub>phenyl(*o*-X<sup>7</sup>, *m*-OR<sup>10</sup>, *p*-X<sup>8</sup>)-[O-phenyl(*o*-OR<sup>9</sup>, *m*-X<sup>9</sup>, *m*-R<sup>16</sup>)]-*m*, where *t* is 0, 1, 2, 3 or 4;
- each R<sup>2</sup> and R<sup>4</sup> are independently selected from the group consisting of hydrogen, R<sup>12</sup> and R<sup>17</sup>;
- R<sup>3</sup> is selected from the group consisting of hydrogen, R<sup>12</sup>, R<sup>17</sup>, mannosyl and O-acetylmanosyl;
- R<sup>5</sup> is selected from COOH, COOR<sup>11</sup>, COR<sup>13</sup>, COR<sup>15</sup>, CH<sub>2</sub>OH, CH<sub>2</sub>halogen, CH<sub>2</sub>R<sup>13</sup>, CHO, CH=NOR<sup>11</sup>, CH=NNR<sup>11</sup>R<sup>12</sup> and C=NNHCONR<sup>11</sup>R<sup>12</sup>;
- R<sup>6a</sup> is selected from OR<sup>12</sup>, OR<sup>17</sup>, OH, O-alkyl-Sug, O-alkenyl-Sug, O-alkynyl-Sug and O-Sug, wherein each alkyl, alkenyl and alkynyl can be unsubstituted or substituted with 1 or more R<sup>19</sup> or Sug and Sug is selected from glucosyl, ristosaminy, N-acetylglucosaminy, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, glucurony, 4-oxovancosaminy, ureido-4-oxovancosaminy and their derivatives;
- R<sup>7</sup> is selected from hydrogen, R<sup>12</sup>, R<sup>17</sup>, Sug and alkyl-Sug, alkenyl-Sug, alkynyl-Sug, wherein each alkyl, alkenyl and alkynyl can be unsubstituted or substituted with 1 or more R<sup>19</sup> or Sug, wherein Sug is selected from glucosyl, mannosyl, ristosaminy, N-acylglucosaminy, N-acylglucurony, glucosaminy, glucurony, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, acosaminy, glucosyl-vancosaminy, glucosyl-4-*epi*-vancosaminy, glucosyl-3-*epi*-vancosaminy, glucosyl-acosaminy, glucosyl-ristosaminy, glucosyl-actinosaminy, glucosyl-rhamnosyl, glucosyl-olivosity, glucosyl-mannosyl, glucosyl-4-oxovancosaminy, glucosyl-ureido-

4-oxovancosaminyl, glucosyl(rhamosyl)-mannosyl-arabinosyl, glucosyl-2-O-Leu and their derivatives.

-  $R^8$  is selected from hydrogen,  $R^{12}$ ,  $R^{17}$ , OH, O-alkyl-Sug, O-alkenyl-Sug, O-alkynyl-Sug and O-Sug, wherein each alkyl, alkenyl and alkynyl can be unsubstituted or substituted with 1 or more  $R^{19}$  or Sug, wherein Sug is selected from mannosyl, galactosyl and galactosyl-galactosyl;

-  $R^9$  is selected from the group consisting of hydrogen,  $R^{12}$ ,  $R^{17}$ , galactosyl and galactosyl-galactosyl;

-  $R^{10}$  is selected from the group consisting of hydrogen,  $R^{12}$ ,  $R^{17}$ , mannosyl ~~or~~ and fucosyl;

- each  $R^{11}$ ,  $R^{11a}$  and  $R^{11b}$  are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, cyloalkyl, cycloalkenyl, cycloalkynyl and a heterocyclic ring, wherein each alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, cyloalkyl, cycloalkenyl, cycloalkynyl and a heterocyclic ring can be substituted with 1 or more  $R^{19}$  or Sug;

-  $R^{12}$  is selected from the group consisting of hydrogen, acyl, amino-protecting group, carbamoyl, thiocarbamoyl,  $SO_2R^{12}$ ,  $S(O)R^{11}$ ,  $COR^{13}$ - $R^{18}$ ,  $COCHR^{18}N(NO)R^{11}$ ,  $COCHR^{18}NR^{11}R^{12}$  and  $COCHR^{18}N^+R^{11}R^{11a}R^{11b}$ , alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, cyloalkyl, cycloalkenyl, cycloalkynyl and a heterocyclic ring, wherein each alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, cyloalkyl, cycloalkenyl, cycloalkynyl and a heterocyclic ring can be substituted with 1 or more  $R^{19}$  or Sug;

-  $R^{12a}$  is selected from the group consisting of hydrogen,  $COCHR^{18}NR^{11}R^{12}$ ,  $COCHR^{18}N(NO)R^{11}$ ,  $COCHR^{18}N^+R^{11}R^{11a}R^{11b}$  and  $COCHR^{18}R^{13}$ ;

-  $R^{13}$  is selected from the group consisting of hydrogen,  $NHR^{12a}$ ,  $NR^{11}R^{12}$ ,  $NR^{11}Sug$ ,  $N^+R^{11}R^{11a}R^{11b}$ ,  $R^{15}$ ,  $NR^{11}C(R^{11a}R^{11b})COR^{15}$  and a group of the formula N- A-  $N^+$ - A,



wherein A is  $-\text{CH}_2-\text{B}-\text{CH}_2-$  and B is  $-(\text{CH}_2)_m-\text{D}-(\text{CH}_2)_r-$ , wherein m and r are from 1 to 4 and D is selected from the group consisting of O, S,  $\text{NR}^{12}$ , and  $\text{N}^+\text{R}^{11}\text{R}^{11a}$ ;

-  $\text{R}^{14}$  is selected from the group consisting of  $\text{CH}_3$ ,  $\text{C}=\text{O}$ ,  $\text{CHOH}$ ,  $\text{C}=\text{NOR}^{11}$ ,  $\text{CHNHOR}^{11}$ ,  $\text{C}=\text{NNR}^{11}\text{R}^{12}$ ,  $\text{C}=\text{NNHCONR}^{11}\text{R}^{12}$  and  $\text{CHNHNr}^{11}\text{R}^{12}$ ;

-  $\text{R}^{15}$  is selected from the group consisting of  $\text{N}(\text{R}^{11})\text{NR}^{11a}\text{R}^{12}$ ,  $\text{N}(\text{R}^{11})\text{OR}^{11a}$ , and  $\text{NR}^{11}\text{C}(\text{R}^{11a}\text{R}^{11b})\text{COR}^{13}$ ;

-  $\text{R}^{16}$  is selected from a the group consisting of the formula  $\text{R}-\text{R}^5$  or  $\text{CH}(\text{NH}_2)\text{CH}_2\text{OH}$ ;

-  $\text{R}^{17}$  is selected from the group consisting of  $\text{SO}_3\text{H}$ ,  $\text{SiR}^{11}\text{R}^{11a}\text{R}^{11b}$ ,  $\text{SiOR}^{11}\text{OR}^{11a}\text{OR}^{11b}$ ,  $\text{PR}^{11}\text{R}^{11a}$ ,  $\text{P}(\text{O})\text{R}^{11}\text{R}^{11a}$ , and  $\text{P}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$ ;

-  $\text{R}^{18}$  is selected from the group consisting of hydrogen,  $\text{R}^1$ ,  $\text{CH}_3$ ,  $\text{CH}_2\text{CH}(\text{CH}_3)_2$ , phenyl(*p*-OH, *m*-Cl), phenyl-rhamnose-*p*, phenyl-(rhamnose-galactose)-*p*, phenyl-(galactose-galactose)-*p*, and phenyl-O-methylrhamnose-*p*;

-  $\text{R}^{19}$  is selected from the group consisting of hydrogen, halogen, SH,  $\text{SR}^{20}$ , OH,  $\text{OR}^{20}$ ,  $\text{COOH}$ ,  $\text{COR}^{20}$ ,  $\text{COOR}^{20}$ ,  $\text{NO}_2$ ,  $\text{NH}_2$ ,  $\text{N}(\text{R}^{20})_2\text{NHC}(\text{NH}_2)=\text{NH}$ ,  $\text{CH}(\text{NH}_2)=\text{NH}$ ,  $\text{NHOH}$ ,  $\text{NHNH}_2$ ,  $\text{N}_3$ ,  $\text{NO}$ ,  $\text{CN}$ ,  $\text{N}=\text{NR}^{20}$ ,  $\text{N}=\text{NR}^{12}$ ,  $\text{SOR}^{20}$ ,  $\text{SO}_2\text{R}^{20}$ ,  $\text{PO}_2\text{OR}^{20}$ ,  $\text{PO}_2\text{N}(\text{R}^{20})_2$ ,  $\text{B}(\text{OH})_2$ ,  $\text{B}(\text{OR}^{20})_2$ ,  $\text{CO}$ ,  $\text{CHO}$ , O-Sug,  $\text{NR}^{20}$ -Sug,  $\text{R}^{20}$ ,  $\text{R}^{12}$ ,  $\text{R}^{17}$  and  $\text{R}^{18}$  and each  $\text{R}^{19}$  can be substituted with 1 or more  $\text{R}^{20}$ ;

-  $\text{R}^{20}$  is selected from the group consisting of hydrogen, halogen, SH, OH,  $\text{COOH}$ ,  $\text{NO}_2$ ,  $\text{NH}_2$ ,  $\text{NHC}(\text{NH}_2)=\text{NH}$ ,  $\text{CH}(\text{NH}_2)=\text{NH}$ ,  $\text{NHOH}$ ,  $\text{NHNH}_2$ ,  $\text{N}_3$ ,  $\text{NO}$ ,  $\text{CN}$ , alkyl, alkenyl, alkynyl, aryl, arylallyl, heteroaryl, cycloalkyl, cycloalkenyl, cycloalkynyl and a heterocyclic ring.

25. (previously presented) The glycopeptide antibiotic or derivative thereof according to claim 23, wherein the derivative is not a compound of the group of compounds referred to with the codes 1 to 55 in the description of this application.

26. (previously presented) The glycopeptide antibiotic or derivative thereof according to claim 23, selected from the group of compounds referred to with the codes 56 to 172 in the description of this application.

27. (previously presented) A composition containing a glycopeptide antibiotic or derivative thereof according to claim 23 as an active ingredient.

28. **(currently amended)** A composition ~~for separate, combined or sequential use in the treatment or prophylaxis of anti-viral infections~~, comprising

a) one or more compounds according to claim 23, and,

b) one or more compounds effective in the treatment or prophylaxis of viral infections, ~~including Retroviral, Flaviviral, Herpes or Coronaviral enzyme or entry inhibitors, in proportions such as to provide a synergistic effect in the said treatment or prophylaxis.~~

29 - 38. **(canceled)**

39. **(new)** The composition of claim 28, wherein said one or more compounds effective in the treatment or prophylaxis of viral infections is/are selected from the group consisting of Retroviral, Flaviviral, Herpes, and Coronaviral enzyme or entry inhibitors.

40. **(new)** The glycopeptide antibiotic or derivative thereof according to claim 23 that has the structure of Formula I.

41. **(new)** The glycopeptide antibiotic or derivative thereof according to claim 23 that has the structure of Formula II.

42. **(new)** The glycopeptide antibiotic or derivative thereof according to claim 23 that has the structure of Formula III.